CENPA-CAD Complex Regulates DNA Replication in Eukaryotic Cells

Target Name: CENPA-CAD (nucleosome distal) complex

NCBI ID: P43027

CENPA-CAD (nucleosome distal) complex

Other Name(s): None

CENPA-CAD Complex Regulates DNA Replication in Eukaryotic Cells

The CENPA-CAD (nucleosome distal) complex is a protein complex that is involved in the regulation of DNA replication in eukaryotic cells. It is composed of several subunits, including CENPA, CAD, and DNA-binding proteins that work together to ensure the proper formation and progression of nucleosomes during the replication process.

CENPA is a nucleosome-remodeling protein that uses a unique conformational change to change the top layer of the nucleosome, allowing for the formation of higher fidelity connections between sister chromatids. This process is critical for the stability and accuracy of DNA replication.

CAD is a protein that binds to the template strand of DNA and helps to ensure the proper orientation of the nucleosome during the replication process. It also plays a role in the regulation of the timing of the replication process by controlling the activity of the complex.

DNA-binding proteins, such as DBP1 and DBP2, are essential for the proper functioning of the CENPA-CAD complex. They interact with the nucleosome to ensure that the complex is properly assembled and that the DNA replication process proceeds smoothly.

The CENPA-CAD complex is a critical regulator of DNA replication in eukaryotic cells. It has been implicated in the development and progression of numerous diseases, including cancer, and is Therefore, it is a potential drug target and biomarker.

One of the key advantages of the CENPA-CAD complex is its ability to interact with multiple DNA replication factors, including the template strand, the single-stranded DNA binding protein DNSP, and the double-stranded DNA binding protein SSBP. This makes it a versatile target for drugs that are aimed at preventing or inhibiting DNA replication in cancer cells.

Another potential mechanism by which the CENPA-CAD complex may be targeted by drugs is its role in the regulation of the timing of DNA replication. Many drugs that are used to treat cancer have been shown to disrupt the timing of DNA replication, leading to the formation of rogue copies of the original DNA sequence that can lead to the development of cancer. The CENPA-CAD complex plays a role in regulating the timing of DNA replication, and drugs that are able to inhibit its activity may be effective in treating cancer.

The CENPA-CAD complex is also a potential biomarker for cancer, as its activity can be easily measured and correlated with the growth of cancer cells. This makes it an attractive target for researchers who are looking for new ways to diagnose and treat cancer.

In conclusion, the CENPA-CAD (nucleosome distal) complex is a protein complex that is involved in the regulation of DNA replication in eukaryotic cells. It is composed of several subunits, including CENPA, CAD, and DNA-binding proteins that work together to ensure the proper formation and progression of nucleosomes during the replication process. The CENPA-CAD complex is a potential drug target and biomarker for the treatment of cancer, as it is involved in the regulation of DNA replication and has been implicated in the development and progression of many diseases. Further research is needed to fully understand the role of the CENPA-CAD complex in the regulation of DNA replication and to develop new treatments for cancer.

Protein Name: CENPA-CAD (nucleosome Distal) Complex

The "CENPA-CAD (nucleosome distal) complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CENPA-CAD (nucleosome distal) complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets